Charlene Mantia

942 total citations
52 papers, 657 citations indexed

About

Charlene Mantia is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Charlene Mantia has authored 52 papers receiving a total of 657 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 23 papers in Surgery and 19 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Charlene Mantia's work include Bladder and Urothelial Cancer Treatments (21 papers), Cancer Immunotherapy and Biomarkers (21 papers) and Renal cell carcinoma treatment (9 papers). Charlene Mantia is often cited by papers focused on Bladder and Urothelial Cancer Treatments (21 papers), Cancer Immunotherapy and Biomarkers (21 papers) and Renal cell carcinoma treatment (9 papers). Charlene Mantia collaborates with scholars based in United States, United Kingdom and France. Charlene Mantia's co-authors include Jeffrey I. Zwicker, David F. McDermott, Mäneka Puligandla, Erik J. Uhlmann, Donna Neuberg, Griffin M. Weber, Guru Sonpavde, Toni K. Choueiri, Bradley A. McGregor and Praful Ravi and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Charlene Mantia

46 papers receiving 653 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Charlene Mantia United States	13	281	244	139	134	126	52	657
A. Vignoli Italy	5	136 0.5×	99 0.4×	158 1.1×	76 0.6×	79 0.6×	7	499
Hiroshi Kawamata Japan	16	163 0.6×	149 0.6×	40 0.3×	175 1.3×	238 1.9×	54	595
Kevin Sheng‐Po Yuan Taiwan	13	161 0.6×	216 0.9×	34 0.2×	243 1.8×	56 0.4×	20	580
M. Sinn Germany	9	291 1.0×	102 0.4×	142 1.0×	106 0.8×	69 0.5×	19	517
Ji Hyun Lee South Korea	11	331 1.2×	162 0.7×	49 0.4×	117 0.9×	83 0.7×	49	544
G. A. T. Hawson Australia	11	136 0.5×	166 0.7×	109 0.8×	196 1.5×	116 0.9×	24	664
Annachiara Mitrugno United States	14	328 1.2×	103 0.4×	112 0.8×	54 0.4×	184 1.5×	18	688
Sandra Régina France	13	102 0.4×	80 0.3×	234 1.7×	254 1.9×	147 1.2×	24	696
Virtudes Vila Spain	13	88 0.3×	110 0.5×	59 0.4×	55 0.4×	167 1.3×	32	491
Jean-Paul de Vries Netherlands	15	52 0.2×	311 1.3×	51 0.4×	278 2.1×	124 1.0×	31	719

Countries citing papers authored by Charlene Mantia

Since Specialization

Citations

This map shows the geographic impact of Charlene Mantia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charlene Mantia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charlene Mantia more than expected).

Fields of papers citing papers by Charlene Mantia

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charlene Mantia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charlene Mantia. The network helps show where Charlene Mantia may publish in the future.

Co-authorship network of co-authors of Charlene Mantia

This figure shows the co-authorship network connecting the top 25 collaborators of Charlene Mantia. A scholar is included among the top collaborators of Charlene Mantia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charlene Mantia. Charlene Mantia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hansen, Aaron R., Alison Yan Zhang, Valentina Boni, et al.. (2025). A multicenter, open-label phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 alterations (SURF301).. Journal of Clinical Oncology. 43(5_suppl).

Reich, Amanda J., et al.. (2025). Examining Patient Characteristics in Bladder Cancer Clinical Trials Involving Immunotherapy. Journal of Clinical Medicine. 14(3). 879–879.

McGregor, Bradley A., Lucia Kwak, Guru Sonpavde, et al.. (2024). Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) for metastatic urothelial carcinoma (mUC) treatment-experienced (DAD) and with pembrolizumab (P) in treatment naïve UC (DAD-IO).. Journal of Clinical Oncology. 42(16_suppl). TPS4618–TPS4618. 2 indexed citations

Ravi, Praful, Dory Freeman, Jonathan Thomas, et al.. (2024). Comprehensive multiplexed autoantibody profiling of patients with advanced urothelial cancer. Journal for ImmunoTherapy of Cancer. 12(2). e008215–e008215. 2 indexed citations

Mantia, Charlene, Opeyemi A. Jegede, Elizabeth R. Plimack, et al.. (2024). Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214. Journal for ImmunoTherapy of Cancer. 12(7). e009495–e009495. 6 indexed citations

Johnson, Melissa L., Chun‐Gon Kim, A. W. Tolcher, et al.. (2024). 501LBA LBA Orals: Phase 1 expansion results of IDE397, a first-in-class, oral, MAT2A inhibitor (MAT2Ai) in MTAP deleted(del) non-small cell lung cancer (NSCLC) and urothelial cancer (UC). European Journal of Cancer. 211. 114979–114979. 1 indexed citations

Hansen, Aaron R., Charlene Mantia, Andrew Weickhardt, et al.. (2024). 72 (PB060): TYRA-300, an oral, FGFR3-selective inhibitor: Preliminary pharmacokinetic and pharmacodynamic analysis from SURF301, the multicenter open-label phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 alterations. European Journal of Cancer. 211. 114599–114599.

Skelton, William Paul, Jonathan Thomas, Rohit Jain, et al.. (2024). Impact of Angiotensin Converting Enzyme Inhibitors on Pathologic Complete Response With Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer. Clinical Genitourinary Cancer. 22(5). 102143–102143.

McGregor, Bradley A., Guru Sonpavde, Lucia Kwak, et al.. (2023). The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma. Annals of Oncology. 35(1). 91–97. 51 indexed citations

10.

Iovane, Angelo, et al.. (2023). Intramuscular migration of calcium deposits into the deltoid muscle: two cases of a rare complication of rotator cuff calcific tendinopathy. Journal of Ultrasound. 26(4). 929–933. 1 indexed citations

11.

Spira, Alexander I., Ranee Mehra, Charlene Mantia, et al.. (2022). 783TiP Phase I study of HFB301001, a novel OX40 agonist monoclonal antibody, in patients with solid tumors selected via Drug Intelligence Science (DIS). Annals of Oncology. 33. S899–S899. 2 indexed citations

12.

Naing, Aung, Charlene Mantia, Daniel Morgensztern, et al.. (2022). First-in-human study of SRF388, a first-in-class IL-27 targeting antibody, as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors.. Journal of Clinical Oncology. 40(16_suppl). 2501–2501. 9 indexed citations

13.

Mantia, Charlene, Opeyemi A. Jegede, Meredith M. Regan, Michael B. Atkins, & David F. McDermott. (2022). Prognostic factors for patients with advanced renal cell carcinoma (aRCC) in the era of first-line (1L) treatment with immune checkpoint inhibitors (ICIs).. Journal of Clinical Oncology. 40(16_suppl). 4544–4544. 2 indexed citations

14.

Johnson, Melissa L., Raid Aljumaily, Miguel A. Villalona‐Calero, et al.. (2022). 492TiP A phase I study of synthetic lethal, IDE397 (MAT2A inhibitor) as a monotherapy and in combination with chemotherapy in advanced solid tumors harboring MTAP deletion. Annals of Oncology. 33. S766–S767. 5 indexed citations

15.

Dranitsaris, George, Jonathan Thomas, Catherine Curran, et al.. (2021). An economic analysis comparing health care resource use and cost of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin versus gemcitabine and cisplatin as neoadjuvant therapy for muscle invasive bladder cancer. Urologic Oncology Seminars and Original Investigations. 39(12). 834.e1–834.e7. 7 indexed citations

16.

Regan, Meredith M., Opeyemi A. Jegede, Charlene Mantia, et al.. (2020). 713P Treatment-free survival, with and without toxicity, after immuno-oncology vs targeted therapy for advanced renal cell carcinoma (aRCC): 42-month results of CheckMate 214. Annals of Oncology. 31. S561–S561. 9 indexed citations

17.

Mantia, Charlene & Jeffrey I. Zwicker. (2019). Anticoagulation in the Setting of Primary and Metastatic Brain Tumors. Cancer treatment and research. 179. 179–189. 12 indexed citations

18.

Mantia, Charlene & David F. McDermott. (2019). Vascular endothelial growth factor and programmed death‐1 pathway inhibitors in renal cell carcinoma. Cancer. 125(23). 4148–4157. 25 indexed citations

19.

Uhlmann, Erik J., Mäneka Puligandla, Charlene Mantia, et al.. (2018). Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors. Journal of Thrombosis and Haemostasis. 17(1). 72–76. 84 indexed citations

20.

Mantia, Charlene, Erik J. Uhlmann, Mäneka Puligandla, et al.. (2017). Clinical Relevance of Intracranial Hemorrhage Volume in Primary and Metastatic Brain Tumors. Blood. 130. 2388–2388. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact